The monoclonal antibody was aimed at geographic atrophy, the late stage of dry age-related macular degeneration (dAMD). GlobalData's Maura …



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *